While Illumina completed the takeover of Grail last September, it has maintained the business as a separate subsidiary company while it waits for the outcome of antitrust reviews in the US and Europe.

The Federal Trade Commission's recent challenge to Microsoft's acquisition of Activision has been rejected by a federal court ...

The placement of Illumina in China's unreliable entity list could have disruptive implications. Read why I remain bullish on ...

GRAIL's founding was likely driven by Illumina's desire to realize more value from its NGS technology and a realization that costs and technological capabilities were reaching a point where liquid ...

Q4 2024 Earnings Call Transcript February 6, 2025 Illumina, Inc. misses on earnings expectations. Reported EPS is $0.91 EPS, ...

CHICAGO: US cancer diagnostic test maker Grail, which was due to list its shares on the Nasdaq yesterday after being spun out of Illumina, is betting that commercial partnerships with health ...

ILMN reported fourth-quarter 2024 adjusted earnings per share (EPS) of 86 cents, which missed the Zacks Consensus Estimate of ...

After China placed Illumina on a government watchlist this week, in response to new tariffs imposed by the Trump ...

Grail spun off from Illumina last year, and is developing a number of early detection cancer screening products. Last week, Grail said it sees fiscal 2025 sales of its Galleri blood test up 20% to ...

For all of last year, Illumina’s net loss grew 5% from $1.161 billion to $1.223 billion, on revenue that fell 3% from $4.505 ...

The ECJ’s Illumina/Grail judgment has curtailed the Commission’s direct oversight of certain transactions, thereby elevating the need for national "call-in" powers. These call-in regimes ...

Please be advised that today's conference is being recorded. I would now like to hand the conference over to Sally Schwartz, Vice President of Investor Relations. Hello everyone and welcome to our ...